Intellia Therapeutics Inc

13. Nov. 2026, 23:01 UTC

Intellia Therapeutics, Inc. shares rose in after-market trading, recovering from three sessions of declines.

12. Nov. 2026, 23:01 UTC

Intellia Therapeutics, Inc. is trading higher in after-market hours, following Prime Medicine's third-quarter results and announcements regarding its clinical trials and FDA clearance.

11. Nov. 2026, 21:06 UTC

Intellia Therapeutics, Inc. shares are advancing, having peaked earlier in the session before pulling back, amid overall solid market performance.

10. Nov. 2026, 23:06 UTC

Intellia Therapeutics, Inc. is moving modestly higher in after-market hours amid a broad market uptick, influenced by the U.S. Consumer Price Index for October.

9. Nov. 2026, 23:06 UTC

Intellia Therapeutics, Inc. shares declined in after-market trading, continuing a downward trajectory following three consecutive higher daily closes.

6. Nov. 2026, 20:16 UTC

State Street SPDR S&P Biotech ETF is higher, moving in sympathy with strong earnings from key holdings like Moderna. Intellia Therapeutics shares also advance.

5. Nov. 2026, 21:04 UTC

Intellia Therapeutics reports a Q3 net loss of $127.5 million, missing EPS estimates by $0.11 and revenue expectations of $10.23 million.

4. Nov. 2026, 21:07 UTC

Intellia Therapeutics completes enrollment in Phase 3 MAGNITUDE-2 trial for nexiguran ziclumeran, targeting hereditary transthyretin amyloidosis with polyneuropathy.

3. Nov. 2026, 23:32 UTC

Intellia Therapeutics will present new clinical data at two medical meetings in November, contributing to its shares trading higher in after-market hours.

2. Nov. 2026, 23:16 UTC

Intellia Therapeutics, Inc. advanced modestly in after-market hours on Monday, trading slightly higher.

30. Okt. 2026, 20:03 UTC

Intellia Therapeutics shares fell sharply, continuing a downward trend since Thursday, as negative sentiment lingers from ARKG's decline after a position sell-off.

29. Okt. 2026, 23:01 UTC

Intellia Therapeutics, Inc. is trading lower in after-market hours, continuing a downward trend linked to declines in the ARK Genomic Revolution ETF and broader market weakness.

28. Okt. 2026, 23:02 UTC

Intellia Therapeutics shares are moving lower in after-market trading, reflecting broader market declines influenced by rising Treasury yields and a widening trade deficit.

27. Okt. 2026, 20:02 UTC

Intellia Therapeutics, Inc. shares are sharply higher, reflecting a shift in momentum after a series of higher daily closes since Monday's close.

26. Okt. 2026, 23:31 UTC

Intellia Therapeutics Inc shares rose during after-market hours on Monday, recovering from earlier losses but remaining below their 20-day moving average.

23. Okt. 2026, 20:07 UTC

Intellia Therapeutics Inc shares are modestly higher, recovering from a significant drop earlier, but remain under pressure and below their 20-day moving average.

22. Okt. 2026, 20:07 UTC

Intellia Therapeutics Inc shares are declining amid significant losses in the ARK Genomic Revolution ETF, reflecting ongoing weakness in the biotechnology sector.

21. Okt. 2026, 23:06 UTC

Intellia Therapeutics Inc shares advanced in after-market trading, supported by gains in broader equity markets following a decline in U.S. crude oil inventories.

19. Okt. 2026, 19:26 UTC

Intellia Therapeutics appoints Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer to support the launch of lonvo-z.

17. Okt. 2026, 00:01 UTC

Intellia Therapeutics Inc shares are trading lower in after-market hours, having retraced from earlier gains and reaching a low for the session.

16. Okt. 2026, 23:41 UTC

Intellia Therapeutics Inc shares are trading lower in after-market hours, reflecting broader market declines amid concerns over potential Federal Reserve rate hikes.

15. Okt. 2026, 22:51 UTC

Intellia Therapeutics Inc saw a notable increase in after-market trading, advancing steadily from a low to a high since Thursday's close.

14. Okt. 2026, 23:06 UTC

Intellia Therapeutics Inc shares are trading lower in after-market hours, continuing a decline that began earlier in the session after a brief peak.

13. Okt. 2026, 20:07 UTC

Intellia Therapeutics appointed Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026.

12. Okt. 2026, 22:52 UTC

Intellia Therapeutics Inc advanced in after-market trading, settling 4.53% above its 20-day moving average and near the upper end of its one-month range.

9. Okt. 2026, 20:07 UTC

Intellia Therapeutics Inc shares are advancing amid a broader market rally, regaining momentum after pulling back earlier in the session.

8. Okt. 2026, 20:02 UTC

Intellia Therapeutics Inc shares are sharply higher, continuing an upward trend since Wednesday, currently positioned significantly above its 20-day moving average.

7. Okt. 2026, 19:56 UTC

Intellia Therapeutics Inc shares fell sharply, reflecting broader biotechnology sector weakness and a decline in the ARK Genomic Revolution ETF amid notable volatility.

6. Okt. 2026, 23:05 UTC

Intellia Therapeutics Inc is experiencing a slight increase in after-market trading, positioned near the upper end of its one-month range.

5. Okt. 2026, 23:06 UTC

Intellia Therapeutics Inc's shares traded modestly lower during after-market hours, influenced by declines in Beam Therapeutics Inc and Recursion Pharmaceuticals Inc.